672 related articles for article (PubMed ID: 27437696)
1. Secukinumab: a promising therapeutic option in spondyloarthritis.
Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
Braun J; Kiltz U; Heldmann F; Baraliakos X
Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
[TBL] [Abstract][Full Text] [Related]
3. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
4. The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.
Smith JA
Curr Rheumatol Rep; 2016 Jun; 18(6):33. PubMed ID: 27105640
[TBL] [Abstract][Full Text] [Related]
5. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.
Paramarta JE; De Rycke L; Ambarus CA; Tak PP; Baeten D
Rheumatology (Oxford); 2013 Oct; 52(10):1873-8. PubMed ID: 23861532
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
7. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
Smolen JS; Braun J; Dougados M; Emery P; Fitzgerald O; Helliwell P; Kavanaugh A; Kvien TK; Landewé R; Luger T; Mease P; Olivieri I; Reveille J; Ritchlin C; Rudwaleit M; Schoels M; Sieper J; Wit Md; Baraliakos X; Betteridge N; Burgos-Vargas R; Collantes-Estevez E; Deodhar A; Elewaut D; Gossec L; Jongkees M; Maccarone M; Redlich K; van den Bosch F; Wei JC; Winthrop K; van der Heijde D
Ann Rheum Dis; 2014 Jan; 73(1):6-16. PubMed ID: 23749611
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic arthritis and spondyloarthritis assessment and management update.
Mease P
Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
Braun J; Baraliakos X; Kiltz U
Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
Ceribelli A; Motta F; Vecellio M; Isailovic N; Ciccia F; Selmi C
Front Immunol; 2021; 12():622770. PubMed ID: 34149686
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.
van Mens LJJ; van de Sande MGH; Menegatti S; Chen S; Blijdorp ICJ; de Jong HM; Fluri IA; Latuhihin TE; van Kuijk AWR; Rogge L; Yeremenko NG; Baeten DLP
Arthritis Rheumatol; 2018 Dec; 70(12):1994-2002. PubMed ID: 29869838
[TBL] [Abstract][Full Text] [Related]
15. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents.
Toussirot E
Expert Opin Pharmacother; 2017 Feb; 18(3):275-282. PubMed ID: 28099816
[TBL] [Abstract][Full Text] [Related]
16. New evidence on the management of spondyloarthritis.
Sieper J; Poddubnyy D
Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
[TBL] [Abstract][Full Text] [Related]
17. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
18. IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?
Atzeni F; Siragusano C; Masala IF; Antonio C; Valentina P; D'Angelo S
Expert Opin Biol Ther; 2022 Jul; 22(7):843-853. PubMed ID: 35722768
[TBL] [Abstract][Full Text] [Related]
19. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
20. Biological therapies in the spondyloarthritides--the current state.
Braun J; Sieper J
Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
